Long-term use of proton pump inhibitor drugs have been linked to kidney problems and cancer.
Academic rigor, journalistic flair
Articles on Drug safety
Displaying 1 - 20 of 32 articles
If you want to know more about a drug, Health Canada provides information online through several websites. However, some information appears to be getting harder to find.
The US Food and Drug Administration has reported that the decongestant phenylephrine, taken in oral form, does not work.
Horseshoe crabs play a unique role in medicine, but they’re also ecologically important in their home waters along the Atlantic coast. Can regulators balance the needs of humans and nature?
Health Canada continues to monitor newly approved drugs to determine if the benefits identified in the pre-market trials hold up to further scrutiny. Canadians need better access to that information.
As the government’s oldest consumer protection agency, the FDA has long butted up against drugmakers, activists and politicians. But undermining its work could be harmful to patient health and safety.
When drugs are taken off the market because they are either unsafe or don’t work, do pharma companies admit that there are problems? Or do they deny the evidence?
It is important that herbal medicine be checked for its safety, its potential to treat particular ailments, and to ascertain its chemical components.
COVID-19 has exacerbated a backlog of domestic and foreign drug manufacturing inspections that the FDA is still too short-staffed to adequately deal with.
Vaccine manufacturing is complex, with lots of potential points for errors. But it also has extensive quality control checks and approvals.
The FDA recalled commonly used heartburn and ulcer medication ranitidine in April 2020. But new research suggests less reason for alarm.
Health Canada devotes far more resources to getting new drugs onto the market compared to making sure that drugs already being sold are safe.
Will a vaccine for COVID-19 be safe? Animal testing, human clinical trials and post-approval surveillance give us good grounds to believe that a future approved vaccine will work and be safe.
The idea that we can sit down calmly and rationally and explain to our children how they can take drugs safely overlooks a bundle of emotional issues.
There are many ways to reduce harm from drugs at music festivals beyond the much publicised pill testing. Here’s what else we can do.
Deliberately infecting people with a disease-causing agent as part of carefully considered medical research can be ethically acceptable or even necessary.
A new book, ‘The Thalidomide Catastrophe,’ raises new questions about the conduct of corporations involved. It is the duty of governments to find out the answers.
The FDA recently issued a draft guidance for testing drugs in pregnant women. Here’s why it’s a good thing.
There’s a common, popular and well-studied method to ensure new technologies are safe and effective for public use – even if researchers don’t fully understand how they work.
Health Canada proposes to increase fees to the pharmaceutical industry for prescription drug approval. This will compromise drug safety and is a risk to the health of the Canadian public.
Top contributors
-
Joel Lexchin is a Friend of The Conversation.Professor Emeritus of Health Policy and Management, York University, Canada
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Associate Professor of Comparative Effectiveness and Outcomes Research, University of Connecticut
-
Assistant Professor, Bond University
-
Professor in Pharmaceutical Policy, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Reader in Clinical Pharmacology and Medical Education, Queen Mary University of London
-
Associate Professor in Mechanical Engineering, Texas A&M University
-
Associate Professor, Mental Health and Addiction, Rural Health Research Institute, Charles Sturt University
-
Research Fellow in African Studies, The University of Edinburgh
-
Senior Research Fellow, University of Oxford
-
Doctoral Student in Biochemistry, University of Washington
-
Professor in Developmental Biology, University of Aberdeen
-
Emeritus Professor of Clinical Sciences, University of Bristol
-
Adjunct Professor at the National Drug Research Institute (Melbourne based), Curtin University
-
Associate Professor and clinical academic gastroenterologist, Western Sydney University
